Literature DB >> 17684335

A human rhinovirus model of chronic obstructive pulmonary disease exacerbations.

Marco Contoli1, Gaetano Caramori, Patrick Mallia, Alberto Papi, Sebastian L Johnston.   

Abstract

Chronic obstructive pulmonary disease (COPD) exacerbations are common events that punctuate the natural history of COPD contributing to disease severity progression and being the major cause of COPD-related morbidity and mortality. Currently available pharmacological strategies are only partially effective at reducing or preventing COPD exacerbations. Viral infections are the most frequent cause of COPD exacerbations. The recent development of a human experimental model of rhinovirus-induced COPD exacerbations represents an innovative tool with the potential to increase our understanding of the inflammatory and immunological mechanisms that lead COPD patients to exacerbate after respiratory virus infections. Moreover this model will provide the opportunity to test, in a carefully controlled setting, novel pharmacological compounds with a potential for treating and preventing COPD exacerbations. In this chapter we will focus on the role of viral infections in COPD exacerbations and will discuss preliminary reports regarding the development of this human model of virus-induced COPD exacerbation.

Entities:  

Mesh:

Year:  2007        PMID: 17684335     DOI: 10.1159/000107057

Source DB:  PubMed          Journal:  Contrib Microbiol        ISSN: 1420-9519


  2 in total

Review 1.  The influence of virus infections on the course of COPD.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

Review 2.  Utility of animal and in vivo experimental infection of humans with rhinoviruses in the development of therapeutic agents for viral exacerbations of asthma and chronic obstructive pulmonary disease.

Authors:  Alfred M Del Vecchio; Patrick J Branigan; Elliot S Barnathan; Susan K Flavin; Philip E Silkoff; Ronald B Turner
Journal:  Pulm Pharmacol Ther       Date:  2014-11-13       Impact factor: 3.410

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.